title: Visual loss in pregnant women with pituitary adenomas.
abstract: OBJECTIVE
  To investigate the potential risk for developing visual loss during single or multiple pregnancies in women with pituitary adenomas.
  
  
  METHODS
  Cohort study.
  
  
  METHODS
  Referral center of a neuro-ophthalmology service.
  
  
  METHODS
  65 consecutive women with pituitary adenomas who had not been previously treated with surgery or radiation were monitored during 111 pregnancies. Sixty had increased levels of serum prolactin or growth hormone and 5 did not.
  
  
  METHODS
  Visual field or acuity loss was compared with the baseline size of the adenoma measured on the coronal view of the computed tomographic or magnetic resonance image.
  
  
  RESULTS
  Computed tomography or magnetic resonance imaging showed a definitive tumor (> 0.3 cm, vertical height) in 57 patients, 8 of whom had macroadenomas (> or = 1.1 cm). Visual field loss occurred in 6 of 8 primiparous patients, all with adenomas greater than 1.1 cm (range, 1.2 to 2.5 cm). None of the 57 patients (95% CI, 0% to 6.3%) with a microadenoma or presumed microadenoma of 1 cm or smaller developed visual loss after as many as four full-term pregnancies.
  
  
  CONCLUSIONS
  The risk for developing visual loss during single or multiple pregnancies in patients with microadenomas was small. Six of eight pregnant women with macroadenomas, however, developed visual field loss during pregnancy.
authors.affiliation: New York University Medical Center, New York.
authors.forename: M J
authors.initials: MJ
authors.lastname: Kupersmith
authors.forename: C
authors.initials: C
authors.lastname: Rosenberg
authors.forename: D
authors.initials: D
authors.lastname: Kleinberg
mesh_terms: D000172:Acromegaly / Q000150:complications; D000236:Adenoma / Q000150:complications* / Q000473:pathology; D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D010911:Pituitary Neoplasms / Q000150:complications* / Q000473:pathology; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000473:pathology; D015175:Prolactinoma / Q000188:drug therapy / Q000473:pathology; D012307:Risk Factors; D014057:Tomography, X-Ray Computed; D014786:Vision Disorders / Q000188:drug therapy / Q000209:etiology*; D014794:Visual Fields
chemical_list: D001971:Bromocriptine